 Shares of Axsome Therapeutics Inc. AXSM, 1.07 jumped 15.5 in premarket trading on Monday after the company said its Alzheimers treatment candidate met the primary and secondary endpoints in a Phase 3 clinical trial, meaning it delayed the time to relapse and prevented agitation among patients. The therapy, AXS-05, was tested in a double-blind, placebo-controlled, randomized study that enrolled 178 patients. 